Cargando…

Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles

Some previous reports have already shown the characterizations of immunomagnetic reduction (IMR). The assay technology involves the utilities of biofunctionalized magnetic nanoparticles to label target biomolecules. However, the detection threshold and interference tests for IMR have not been invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Kai-Wen, Yang, Shieh-Yueh, Hong, Yu-Wei, Chieh, Jen-Jie, Yang, Che-Chuan, Horng, Herng-Er, Wu, Chau-Chung, Hong, Chin-Yih, Yang, Hong-Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356210/
https://www.ncbi.nlm.nih.gov/pubmed/22619536
http://dx.doi.org/10.2147/IJN.S28245
_version_ 1782233521218125824
author Huang, Kai-Wen
Yang, Shieh-Yueh
Hong, Yu-Wei
Chieh, Jen-Jie
Yang, Che-Chuan
Horng, Herng-Er
Wu, Chau-Chung
Hong, Chin-Yih
Yang, Hong-Chang
author_facet Huang, Kai-Wen
Yang, Shieh-Yueh
Hong, Yu-Wei
Chieh, Jen-Jie
Yang, Che-Chuan
Horng, Herng-Er
Wu, Chau-Chung
Hong, Chin-Yih
Yang, Hong-Chang
author_sort Huang, Kai-Wen
collection PubMed
description Some previous reports have already shown the characterizations of immunomagnetic reduction (IMR). The assay technology involves the utilities of biofunctionalized magnetic nanoparticles to label target biomolecules. However, the detection threshold and interference tests for IMR have not been investigated in detail. In this study, alpha-fetoprotein (AFP) was used as a target biomolecule. The signals for AFP solutions of various concentrations, or with interfering materials, were detected via IMR. These samples were also used for characterizing the detection threshold and interference with enzyme-linked immunosorbent assay (ELISA). The results of assaying AFP level with IMR and ELISA were compared. The detection threshold for assaying AFP with IMR was found to be 3 ng/mL, which is 15 times lower than that of ELISA, and definitely suppresses false negative. For the interfering materials noted commonly in serum such as hemoglobin, bilirubin, triglyceride, and vascular endothelial growth factor, there was no detectable interfering effect when assaying AFP with IMR. Several serum samples from normal people and liver-tumor-bearing patients were used for the detections of AFP concentration via IMR. These results reveal the feasibilities of assaying AFP in blood using IMR, as well as achieving high-sensitive and high-specific assay for AFP.
format Online
Article
Text
id pubmed-3356210
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33562102012-05-22 Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles Huang, Kai-Wen Yang, Shieh-Yueh Hong, Yu-Wei Chieh, Jen-Jie Yang, Che-Chuan Horng, Herng-Er Wu, Chau-Chung Hong, Chin-Yih Yang, Hong-Chang Int J Nanomedicine Original Research Some previous reports have already shown the characterizations of immunomagnetic reduction (IMR). The assay technology involves the utilities of biofunctionalized magnetic nanoparticles to label target biomolecules. However, the detection threshold and interference tests for IMR have not been investigated in detail. In this study, alpha-fetoprotein (AFP) was used as a target biomolecule. The signals for AFP solutions of various concentrations, or with interfering materials, were detected via IMR. These samples were also used for characterizing the detection threshold and interference with enzyme-linked immunosorbent assay (ELISA). The results of assaying AFP level with IMR and ELISA were compared. The detection threshold for assaying AFP with IMR was found to be 3 ng/mL, which is 15 times lower than that of ELISA, and definitely suppresses false negative. For the interfering materials noted commonly in serum such as hemoglobin, bilirubin, triglyceride, and vascular endothelial growth factor, there was no detectable interfering effect when assaying AFP with IMR. Several serum samples from normal people and liver-tumor-bearing patients were used for the detections of AFP concentration via IMR. These results reveal the feasibilities of assaying AFP in blood using IMR, as well as achieving high-sensitive and high-specific assay for AFP. Dove Medical Press 2012 2012-04-17 /pmc/articles/PMC3356210/ /pubmed/22619536 http://dx.doi.org/10.2147/IJN.S28245 Text en © 2012 Huang et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Huang, Kai-Wen
Yang, Shieh-Yueh
Hong, Yu-Wei
Chieh, Jen-Jie
Yang, Che-Chuan
Horng, Herng-Er
Wu, Chau-Chung
Hong, Chin-Yih
Yang, Hong-Chang
Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles
title Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles
title_full Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles
title_fullStr Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles
title_full_unstemmed Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles
title_short Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles
title_sort feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356210/
https://www.ncbi.nlm.nih.gov/pubmed/22619536
http://dx.doi.org/10.2147/IJN.S28245
work_keys_str_mv AT huangkaiwen feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles
AT yangshiehyueh feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles
AT hongyuwei feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles
AT chiehjenjie feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles
AT yangchechuan feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles
AT hornghernger feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles
AT wuchauchung feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles
AT hongchinyih feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles
AT yanghongchang feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles